Of note, after the angioplasty procedure, considering the presence of muscular disease, the patient was prescribed a PCSK9 inhibitor with an effective control over LDL levels and an excellent tolerability profile, confirming what has been previously reported concerning the safety of such drugs in McArdle patients [10]. The gene discussed is PCSK9; the disease is muscular disease.